drugset / Trial / NCT06294639

ED50 of Esketamine for Laser Treatment in Children

NCT06294639

NaSequentialOpen-labelOther

Summary

There is limited research on the combined use of esketamine and alfentanil for anesthesia during facial laser treatment in pediatric patients, and the effective dosage of esketamine for inhibiting body movement remains unclear. We explore the effective dose of esketamine combined with alfentanil for the inhibition of body movement during facial laser treatment in pediatric patients.

Timeline

Start
2024-03-27
Primary completion
2025-03-27
Completion
2025-04-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Esketamine Other / unclassified Intravenous

Indications

No indication recorded.